- Home
- Publications
- Publication Search
- Publication Details
Title
Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4
Authors
Keywords
-
Journal
Dermatologic Therapy
Volume 26, Issue 2, Pages 135-148
Publisher
Wiley
Online
2013-04-04
DOI
10.1111/dth.12027
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A multicenter phase II trial of adjuvant erlotinib in patients with resected non-small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR): Toxicity evaluation.
- (2017) J. W. Neal et al. JOURNAL OF CLINICAL ONCOLOGY
- Pruritus: still a challenge
- (2012) Paulo Rowilson Cunha et al. ANAIS BRASILEIROS DE DERMATOLOGIA
- The effect of pimecrolimus on innate immunity in subjects with atopic dermatitis: a double-blind, randomized, vehicle-controlled study
- (2012) M. Afshar et al. BRITISH JOURNAL OF DERMATOLOGY
- Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva
- (2012) N.S. Horowitz et al. GYNECOLOGIC ONCOLOGY
- Tumor Response and Toxicity of Neoadjuvant Erlotinib in Patients With Early-Stage Non–Small-Cell Lung Cancer
- (2012) Eva E. Schaake et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
- (2012) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management
- (2012) I. Manousaridis et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study
- (2012) Tudor Ciuleanu et al. LANCET ONCOLOGY
- Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation
- (2012) S.J. Park et al. LUNG CANCER
- Immunotherapies in Dermatologic Disorders
- (2012) Robyn S. Fallen et al. MEDICAL CLINICS OF NORTH AMERICA
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors
- (2012) L. Peuvrel et al. SUPPORTIVE CARE IN CANCER
- The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash to cetuximab in cancer patients: a meta-analysis
- (2011) Y. Balagula et al. ANNALS OF ONCOLOGY
- A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma
- (2011) J. A. Chan et al. ANNALS OF ONCOLOGY
- Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy
- (2011) B. Coudert et al. ANNALS OF ONCOLOGY
- Recommendations on management of EGFR inhibitor-induced skin toxicity: A systematic review
- (2011) J.M. Baas et al. CANCER TREATMENT REVIEWS
- Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors
- (2011) Peggy A Wu et al. CURRENT OPINION IN ONCOLOGY
- Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors
- (2011) Yevgeniy Balagula et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Cetuximab for the Treatment of Advanced Bronchioloalveolar Carcinoma (BAC): An Eastern Cooperative Oncology Group Phase II Study (ECOG 1504)
- (2011) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin
- (2011) Eve Maubec et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer
- (2011) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2011) Ronald B. Natale et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities
- (2011) Mario E. Lacouture et al. SUPPORTIVE CARE IN CANCER
- Chronic Pruritus in the Absence of Specific Skin Disease
- (2010) Nicoletta Cassano et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Ras and Raf pathways in epidermis development and carcinogenesis
- (2010) F Kern et al. BRITISH JOURNAL OF CANCER
- Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
- (2010) Geoffrey Y. Ku et al. CANCER
- Phase II study of erlotinib for chemotherapy-naïve patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets
- (2010) Dae Ho Lee et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Lack of Correlation between Epidermal Growth Factor Receptor Status and Response to Panitumumab Monotherapy in Metastatic Colorectal Cancer
- (2010) J. R. Hecht et al. CLINICAL CANCER RESEARCH
- Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib
- (2010) Emma Guttman-Yassky et al. EUROPEAN JOURNAL OF CANCER
- A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma
- (2010) Evan M. Hersh et al. INVESTIGATIONAL NEW DRUGS
- Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer
- (2010) Mario E. Lacouture et al. JOURNAL OF CLINICAL ONCOLOGY
- Preliminary evidence for a role of mast cells in epidermal growth factor receptor inhibitor–induced pruritus
- (2010) Peter Arne Gerber et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non-small Cell Lung Cancer: A Phase II Study
- (2010) Kaoru Kubota et al. Journal of Thoracic Oncology
- Cetuximab Monotherapy in Patients with Advanced Non-small Cell Lung Cancer After Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy
- (2010) Joel W. Neal et al. Journal of Thoracic Oncology
- Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
- (2010) Federico Cappuzzo et al. LANCET ONCOLOGY
- Aprepitant for Erlotinib-Induced Pruritus
- (2010) Bruno Vincenzi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- MANAGEMENT OF SKIN RASH DURING EGFR-TARGETED MONOCLONAL ANTIBODY TREATMENT FOR GASTRO INTESTINAL MALIGNANCIES: CANADIAN RECOMMENDATIONS
- (2009) Barb Melosky et al. Current Oncology
- New insights into the pathophysiology and treatment of chronic itch in patients with end-stage renal disease, chronic liver disease, and lymphoma
- (2009) Hui Wang et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- A Phase 2 Clinical Trial of Panitumumab Monotherapy in Japanese Patients with Metastatic Colorectal Cancer
- (2009) K. Muro et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- A prospective randomized trial of topical pimecrolimus for cetuximab-associated acne-like eruption
- (2009) Alon Scope et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer
- (2009) J Ocvirk et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
- Risk of High-Grade Skin Rash in Cancer Patients Treated with Cetuximab – an Antibody against Epidermal Growth Factor Receptor: Systemic Review and Meta-Analysis
- (2009) Xiao Su et al. ONCOLOGY
- Clinical Predictors of Severe Cetuximab-Induced Rash: Observations from 933 Patients Enrolled in North Central Cancer Treatment Group Study N0147
- (2009) Aminah Jatoi et al. ONCOLOGY
- Unanticipated toxicities from anticancer therapies: Survivors’ perspectives
- (2009) Mona Gandhi et al. SUPPORTIVE CARE IN CANCER
- Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer
- (2008) Maura N. Dickler et al. BREAST CANCER RESEARCH AND TREATMENT
- U.S. Food and Drug Administration Approval: Panitumumab for Epidermal Growth Factor Receptor-Expressing Metastatic Colorectal Carcinoma with Progression Following Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Containing Chemotherapy Regimens
- (2008) R. M. Giusti et al. CLINICAL CANCER RESEARCH
- Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148
- (2008) Amit M. Oza et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti–Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment
- (2008) Lawrence Fong et al. JOURNAL OF CLINICAL ONCOLOGY
- Erlotinib for Advanced Non–Small-Cell Lung Cancer in the Elderly: An Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21
- (2008) Paul Wheatley-Price et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study
- (2008) L.D. Locati et al. ORAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now